Start Date
July 31, 2015
Primary Completion Date
June 30, 2016
Study Completion Date
October 31, 2016
PF-03084014
gamma-secretase inhibitor, formulated in tablets for oral administration containing 10 mg, 50 mg and 100 mg. Patient will receive 80 mg, 100 mg or 150 mg twice daily of PF-03084014 with continuous dosing schedule
Lead Sponsor
Pfizer
INDUSTRY